Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI Enters $95 Million China Deal for BioInvent's Checkpoint Inhibitor

publication date: Oct 27, 2020

CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. BI-1206 is a FcγRIIB inhibitor that is being tested as a treatment for hematological and solid tumors. BioInvent is conducting a Phase I/II trial of BI-1206 in combination with PD-1 therapy Keytruda in solid tumors, and with MabThera in non-Hodgkin lymphoma. CASI will be in charge of BI-1206 commercialization in greater China. Headquartered in Maryland, CASI markets oncology drugs in China. More details....

Stock Symbols: (NSDQ: CASI) (OMXS: BINV)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital